A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19

BACKGROUND: Renin-angiotensin aldosterone system inhibitors (RAASi) are commonly used among patients hospitalized with a severe acute respiratory syndrome coronavirus 2 infection coronavirus disease 2019 (COVID-19). We evaluated whether continuation versus discontinuation of RAASi were associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Abhinav, Elharram, Malik, Afilalo, Jonathan, Flannery, Alexandria, Afilalo, Marc, Tselios, Chris, Ni, Jiayi, Ezekowitz, Justin A., Cheng, Matthew P., Ambrosy, Andrew P., Zannad, Faiez, Brophy, James M., Giannetti, Nadia, Bessissow, Amal, Kronfli, Nadine, Marelli, Ariane, Aziz, Haya, Alqahtani, Mohammad, Aflaki, Mona, Craig, Morgan, Lopes, Renato D., Ferreira, João Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820148/
https://www.ncbi.nlm.nih.gov/pubmed/35143744
http://dx.doi.org/10.1016/j.ahj.2022.01.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820148/
https://www.ncbi.nlm.nih.gov/pubmed/35143744
http://dx.doi.org/10.1016/j.ahj.2022.01.015

Ejemplares similares